[Federal Register Volume 65, Number 33 (Thursday, February 17, 2000)]
[Notices]
[Page 8183]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 00-3776]



[[Page 8183]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: ``Antibodies to Human 
Cripto Protein'' and ``Antibodies Specific for Human Cripto-Related 
Polypeptide CR-3''

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209 (c) (1) and 
37 CFR 404.7 (a) (1) (i), that the National Institutes of Health, 
Department of Health and Human Services, is contemplating the grant of 
an exclusive license to practice the inventions embodied in U.S. Patent 
Application S/N 08/463,616 entitled, ``Antibodies to Human Cripto 
Protein'' filed on June 5, 1995 and now U.S. Patent 5,792,616 which 
issued on August 11, 1998 and U.S. Patent Application S/N 08/464,023 
entitled, ``Antibodies Specific for Human Cripto-Related Polypeptide 
CR-3'' filed on June 5, 1995 and now U.S. Patent 5,854,399 which issued 
on December 29, 1998 to Biogen, Inc. of Cambridge, Massachusetts. The 
patent rights in these inventions have been assigned to the United 
States of America.
    The prospective exclusive license territory will be for the United 
States and the field of use may be limited to therapeutics for the 
treatment and prevention of diseases in humans.

DATES: Only written comments and/or license applications which are 
received by the National Institutes of Health on or before April 17, 
2000 will be considered.

ADDRESSES: Requests for copies of the patent, inquiries, comments and 
other materials relating to the contemplated exclusive license should 
be directed to: Richard U. Rodriguez, M.B.A., Technology Licensing 
Specialist, Office of Technology Transfer, National Institutes of 
Health, 6011 Executive Boulevard, Suite 325, Rockville, MD. 20852-3804. 
Telephone: (301) 496-7056, X287; Facsimile (301) 402-0220; E-mail 
[email protected].

SUPPLEMENTARY INFORMATION: U.S. Patent 5,792,616 claims both polyclonal 
and monoclonal antibodies that bind to a human cripto protein (CR-1) 
and a method of screening for the expression of a cripto protein in a 
tissue sample. U.S. Patent 5,854,399 claims a monoclonal antibody that 
binds to a human cripto-related polypeptide-3 (CR-3) and not to CR-1.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be granted unless within sixty 
(60) days from the date of this published notice, the NIH receives 
written evidence and argument that establish that the grant of the 
license would not be consistent with the requirements of 35 U.S.C. 209 
and 37 CFR 404.7.
    Applications for a license in the field of use filed in response to 
this notice will be treated as objections to the grant of the 
contemplated exclusive license. Comments and objections submitted to 
this notice will not be made available for public inspection and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: February 8, 2000.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer.
[FR Doc. 00-3776 Filed 2-16-00; 8:45 am]
BILLING CODE 4140-01-P